whytestocks
5 years ago
News: $MYGN FINAL DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline Tomorrow
SAN FRANCISCO , CA / ACCESSWIRE / November 25, 2019 / Hagens Berman urges Myriad Genetics, Inc. (NASDAQ:MYGN) investors who have suffered losses in excess of $50,000 to submit their losses now or contact the firm immediately to learn if they qualify to recover compensable damages. On...
Got this from MYGN - FINAL DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline Tomorrow
Cbdpotential
7 years ago
GeneSight® Shown to Statistically Significantly Improve Generalized Anxiety Disorder Treatment Response and Decrease Benzodi...
Source: GlobeNewswire Inc.
Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced new positive results for the GeneSight® test in patients with Generalized Anxiety Disorder (GAD). The study found that GeneSight guided treatment statistically significantly improved treatment response in patients with GAD and decreased the use of benzodiazepines which have potential for abuse and dependence. The data were presented at the 25th World Congress of Psychiatric Genetics meeting in Orlando, Fla with co-investigators from Toronto’s Centre for Addiction and Mental Health (CAMH).
“Anxiety is one of the most common mental health disorders, affecting 60 million Americans or three times the number of people with depression,” said Bryan Dechairo, Ph.D., executive vice president of Clinical Development, Myriad Genetics. “This new study provides strong evidence that the GeneSight test can help physicians personalize treatment for patients with anxiety, leading to more effective treatment and a beneficial reduction in benzodiazepine use.”
This study evaluated data from two separate studies including: CAMH’s Individualized Medicine: Pharmacogenetic Assessment and Clinical Treatment (IMPACT) study, where 315 patients with anxiety disorders were assessed for symptom severity using the GAD-7 questionnaire; and the Medco dataset in which 662 patients who were prescribed at least one benzodiazepine six months pretesting and were followed 12 months post-testing.
The results of the IMPACT study show that medication decisions that were congruent with the GeneSight test results can help guide the treatment of GAD and resulted in a statistically-significant improvement in anxiety symptom severity (p=0.03). The Medco data showed that 18 percent of patients originally taking at least one benzodiazepine ceased the use of benzodiazepines after testing with GeneSight with a significant decrease in benzodiazepine drug counts and refills (p<0.001). The IMPACT study was funded in part by Ontario’s Ministry of Research and Innovation.
For more information about GeneSight, please visit www.genesight.com.
About Anxiety
Anxiety affects one in five people in the United States and one in nine people worldwide and is a leading cause of disability. Anxiety increases the risk for other conditions including depression and substance abuse. Treatment for anxiety includes psychological interventions and pharmacologic therapy. Antidepressants are considered the first line in the treatment of anxiety and benzodiazepines are considered second or third line due to the potential for abuse and dependency.
About GeneSight®
GeneSight is a laboratory-developed pharmacogenomic test that uses cutting edge technology to measure and analyze clinically important genomic variants in the treatment of psychiatric disorders. The results of the GeneSight report can help a clinician understand the way a patient’s unique genomic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenomics, the study of genomic factors that influence an individual’s response to drug treatments, manufacturers’ FDA approved drug labels, peer reviewed scientific and clinical publications, and proven drug pharmacology. Quick turnaround time, combined with a customized report of the patient’s genomic makeup, clinical experience, and other factors can provide information to help a physician make personalized drug treatment choices for each patient.
About Assurex Health
Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN) is a personalized medicine company that specializes in pharmacogenomics and is dedicated to helping physicians determine the right medication for individual patients with neuropsychiatric and other disorders. The company was founded to commercialize industry-leading personalized medicine technology for neuropsychiatric disorders. Assurex Health has licensed technology from Mayo Clinic and Cincinnati Children’s Hospital Medical Center.
For more information about Assurex Health, please visit https://genesight.com/about-assurex-health/ .
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com. Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, EndoPredict, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra DA, GeneSight, EndoPredict and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G
About CAMH
The Centre for Addiction and Mental Health (CAMH) is Canada's largest mental health and addiction teaching hospital, as well as one of the world's leading research centres in its field. CAMH combines clinical care, research, education, policy development and health promotion to help transform the lives of people affected by mental health and addiction issues. CAMH is fully affiliated with the University of Toronto, and is a Pan American Health Organization/World Health Organization Collaborating Centre. For more information, please follow @CAMHnews and @CAMHResearch on Twitter.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to related to data presented at the 25th World Congress of Psychiatric Genetics meeting in Orlando, Fla.; GeneSight testing being able to statistically significantly improve generalized anxiety disorder treatment response and decrease benzodiazepine use; the study providing strong evidence that the GeneSight test can help physicians personalize treatment for patients with anxiety, leading to more effective treatment and a beneficial reduction in benzodiazepine use; and the Company’s strategic directives under the caption “About Myriad Genetics.” These “forward-looking statements” are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of Assurex, Sividon and the Clinic; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading “Risk Factors” contained in Item 1A of our most recent Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.
Media Contact:
Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
TheFinalCD
9 years ago
United States Patent and Trademark Office Grants Patent for Vectra(R) DA
Print
Alert
Myriad Genetics (NASDAQ:MYGN)
Intraday Stock Chart
Today : Tuesday 1 December 2015
Click Here for more Myriad Genetics Charts.
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent No. 9,200,324. The patent, which is expected to expire in 2031, provides intellectual property protection for Crescendo Bioscience's Vectra® DA testing.
Crescendo Bioscience logo
Vectra DA is an advanced blood test for adults with rheumatoid arthritis (RA) and helps patients objectively track their disease activity over time. Vectra DA measures expression levels of twelve biomarkers that are then combined into a single score. The twelve biomarkers measured by Vectra DA are: VCAM-1, EGF, VEGF-A, IL-6, TNF-RI, MMP-1, MMP-3, YKL-40, leptin, resistin, SAA and CRP.
The recently issued patent is co-assigned to Crescendo and the Oklahoma Medical Research Foundation and is the first patent issued relating to Vectra DA. Crescendo will continue to pursue additional patent applications, which if issued, should expand the scope of intellectual property protection for Vectra DA.
"Crescendo's first patent for Vectra DA is significant because it validates the innovation required to bring to market the only objective multi-biomarker test for assessing RA disease activity," said Bernie Tobin, president, Crescendo Bioscience. "The PTO's decision comes at a critical time as we enter the golden era of personalized medicine. In order for personalized medicine to become a reality, strong intellectual property protection is essential because it provides research-based companies like Crescendo with incentives to continue to invest in research and development."
About Vectra® DA
Vectra DA is the only multi-biomarker blood test for rheumatoid arthritis (RA) disease activity that integrates the concentrations of 12 serum proteins associated with RA disease activity into a single objective score, on a scale of 1 to 100, to help physicians make more informed treatment decisions. Vectra DA testing is performed at the Crescendo Bioscience state-of-the-art CLIA (Clinical Laboratory Improvement Amendments) facility. Test results are reported to the physician 5 to 7 days from shipping of the specimen to Crescendo Bioscience. Physicians can receive test results via standard mail, by fax or via the private web portal, VectraView. For more information on Vectra DA, please visit: www.Vectra-DA.com.
About Crescendo Bioscience
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc., is a molecular diagnostics company dedicated to developing and commercializing quantitative blood tests for rheumatoid arthritis (RA) and other autoimmune diseases, located in South San Francisco, Calif. Crescendo Bioscience develops quantitative, objective, reproducible blood tests to provide rheumatologists with deeper clinical insight to help enable more effective management of patients with autoimmune and inflammatory diseases. For more information, please visit the company website at www.CrescendoBio.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G
Safe Harbor Statement
stocktrademan
10 years ago
$MYGN recent news/filings
bearish
## source: finance.yahoo.com
Tue, 21 Apr 2015 13:47:03 GMT ~ Hunt for Deadly Breast Cancer Genes Pools Thousands of Women
read full: http://finance.yahoo.com/news/hunt-deadly-breast-cancer-genes-040117871.html
*********************************************************
Tue, 21 Apr 2015 11:28:00 GMT ~ Startup Pledges To Cut Cost Of Breast Cancer Genetic Testing From $4000 To $249
read full: http://www.forbes.com/sites/matthewherper/2015/04/21/start-up-pledges-to-cut-cost-of-breast-cancer-genetic-testing-from-4000-to-249/?utm_campaign=yahootix&partner=yahootix
*********************************************************
Tue, 21 Apr 2015 05:46:13 GMT ~ Color Genomics Sells $249 Breast Cancer Gene Test to Masses
read full: http://finance.yahoo.com/news/color-genomics-sells-249-breast-054613173.html
*********************************************************
Tue, 21 Apr 2015 04:01:00 GMT ~ Quest Diagnostics, French agency seek to expand breast cancer gene database
read full: http://finance.yahoo.com/news/quest-diagnostics-french-agency-seek-040100912.html
*********************************************************
Thu, 09 Apr 2015 13:45:24 GMT ~ Cowen Thinks 3 Life Science Stocks Can Beat Earnings Estimates
read full: http://247wallst.com/healthcare-business/2015/04/09/cowen-thinks-3-life-science-stocks-can-beat-earnings-estimates/
*********************************************************
$MYGN charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$MYGN company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/MYGN/company-info
Ticker: $MYGN
OTC Market Place: Not Available
CIK code: 0000899923
Company name: Myriad Genetics, Inc.
Incorporated In: DE, USA
$MYGN share structure
## source: otcmarkets.com
Market Value: $2,501,207,122 a/o Apr 20, 2015
Shares Outstanding: 72,985,326 a/o Oct 30, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$MYGN extra dd links
Company name: Myriad Genetics, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/MYGN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/MYGN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=MYGN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=MYGN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=MYGN+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/MYGN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/MYGN/news - http://finance.yahoo.com/q/h?s=MYGN+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/MYGN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/MYGN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/MYGN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/MYGN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/MYGN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/MYGN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/MYGN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/MYGN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=MYGN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/MYGN
DTCC (dtcc.com): http://search2.dtcc.com/?q=Myriad+Genetics%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Myriad+Genetics%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Myriad+Genetics%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/MYGN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/MYGN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/MYGN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/MYGN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/MYGN/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000899923&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/MYGN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/MYGN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/MYGN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/MYGN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=MYGN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=MYGN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/MYGN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=MYGN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=MYGN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=MYGN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=MYGN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=MYGN+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/MYGN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=MYGN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/MYGN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=MYGN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/MYGN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/MYGN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/MYGN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/MYGN/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/MYGN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/MYGN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/MYGN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=MYGN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=MYGN
$MYGN DD Notes ~ http://www.ddnotesmaker.com/MYGN
stocktrademan
10 years ago
Myriad Genetics, Inc. [$MYGN] due diligence
bullish short squeeze
$MYGN
DD Notes ~ http://www.ddnotesmaker.com/MYGN
##### recent news/filings ~ source: finance.yahoo.com
Thu, 26 Jun 2014 22:41:00 GMT ~ Novo, Other Medicals Display Healthy Action
read full: http://news.investors.com/062614-706421-novo-other-medicals-display-healthy-action.htm?ven=yahoocp&src=aurlled&ven=yahoo
*********************************************************
Tue, 10 Jun 2014 20:05:00 GMT ~ Crescendo Bioscience to Present Multiple Studies at 2014 EULAR Meeting
[GlobeNewswire] - Vectra(R) DA Identified Patients in SWEFOT Clinical Study at Higher Risk of Joint Damage
read full: http://finance.yahoo.com/news/crescendo-bioscience-present-multiple-studies-200500660.html
*********************************************************
Mon, 09 Jun 2014 22:53:00 GMT ~ A Few Medical Research Stocks Break Out, Others Basing
read full: http://news.investors.com/060914-704005-medical-research-stocks-leading.htm?ven=yahoocp&src=aurlled&ven=yahoo
*********************************************************
Mon, 09 Jun 2014 21:10:39 GMT ~ MYRIAD GENETICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
read full: http://biz.yahoo.com/e/140609/mygn8-k.html
*********************************************************
Mon, 09 Jun 2014 20:05:00 GMT ~ Myriad Announces Retirement of James Evans, Chief Financial Officer
[GlobeNewswire] - SALT LAKE CITY -- Myriad Genetics, Inc. announced today that James Evans, chief financial officer of Myriad, has notified the Company of his intent to retire in order to attend to family health issues. ...
read full: http://finance.yahoo.com/news/myriad-announces-retirement-james-evans-200500975.html
*********************************************************
##### chart ~ source: stockcharts.com
##### chart ~ source: eoddata.com
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/MYGN/company-info
Ticker: $MYGN
OTC Market Place: Not Available
CIK code: 0000899923
Company name: Myriad Genetics, Inc.
Incorporated In: DE, USA
##### extra dd links
Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000899923&owner=exclude&count=40
Latest filings: http://www.otcmarkets.com/stock/MYGN/filings
Latest financials: http://www.otcmarkets.com/stock/MYGN/financials
Latest news: http://www.otcmarkets.com/stock/MYGN/news - http://finance.yahoo.com/q/h?s=MYGN+Headlines
Major holdings: http://data.cnbc.com/quotes/MYGN/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=MYGN+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/MYGN.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=MYGN
RegSho: http://www.regsho.com/tools/symbol_stats.php?sym=MYGN&search=search
DTCC: http://search2.dtcc.com/?q=Myriad+Genetics%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&q=Myriad+Genetics%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results?term=Myriad+Genetics%2C+Inc.&x=0&y=0
Short Sales: http://www.otcmarkets.com/stock/MYGN/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/MYGN/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/MYGN/research
Historical Prices: http://finance.yahoo.com/q/hp?s=MYGN+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=MYGN+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=MYGN+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=MYGN+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=MYGN+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=MYGN+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=MYGN
Balance Sheet: http://finance.yahoo.com/q/bs?s=MYGN
Cash Flow: http://finance.yahoo.com/q/cf?s=MYGN+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/MYGN
Bloomberg: http://www.bloomberg.com/quote/MYGN:US
Morningstar: http://quotes.morningstar.com/stock/s?t=MYGN
Bussinessweek: http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=MYGN
Barchart: http://www.barchart.com/quotes/stocks/MYGN
OTC Short Report: http://otcshortreport.com/index.php?index=MYGN
Investopedia: http://www.investopedia.com/markets/stocks/MYGN/?wa=0
http://www.pennystocktweets.com/stocks/profile/MYGN
##### last known share structure ~ source: otcmarkets.com
Market Value: $2,912,141,985 a/o
Shares Outstanding: 74,823,792 a/o May 02, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
##### business description ~ source: otcmarkets.com
DD Notes ~ http://www.ddnotesmaker.com/MYGN
surf1944
11 years ago
7:04AM Myriad Genetics: BRCA patent owners and Gene by Gene resolve patent suit; Gene by Gene will cease selling or marketing clinical diagnostic tests within N. America that include analysis of the BRCA1 and/or BRCA2 genes as a standalone test or in conjunction with gene panels (MYGN) 30.57 :
Gene by Gene and Myriad Genetics, the University of Utah Research Foundation, HSC Research and Development Limited Partnership, Endorecherche, and the Trustees of the University of Pennsylvania have reached an agreement to settle the patent infringement lawsuit between them regarding BRCA testing.
Under the agreement and effective immediately, Gene by Gene will cease selling or marketing clinical diagnostic tests within North America that include analysis of the BRCA1 and/or BRCA2 genes as a standalone test or in conjunction with gene panels, but Gene by Gene will continue to offer such tests outside of North America. The Parties have also agreed that Gene by Gene may continue to offer its whole genome and exome products and services, which include the BRCA genes, as well as Gene by Gene's custom array products that test variants for inherited Mendelian disorders, including variants for BRCA1 and BRCA2, worldwide.
The agreement will continue until the earlier of Feb 12, 2016 or the last-to-expire valid patent claim in any of the BRCA patents involved in the case. In return, the Patent Owners have agreed to dismiss the patent infringement case against Gene by Gene without prejudice.
This settlement effectively ends the suit that was filed July 10, 2013, in which the Patent Owners alleged that the testing process employed by Gene by Gene infringes certain claims in patents owned by the Patent Owners covering synthetic DNA and methods-of-use related to the BRCA1 and BRCA2 genes.
TheFinalCD
11 years ago
Myriad's HRD(TM) Test Significantly Predicts Response to Cisplatin Treatment in Patients With Triple Negative Breast Cancer i...
Print
Alert
Myriad Genetics (NASDAQ:MYGN)
Intraday Stock Chart
Today : Saturday 14 December 2013
Click Here for more Myriad Genetics Charts.
Myriad Genetics, Inc. (Nasdaq:MYGN) today presented clinical data at the 2013 San Antonio Breast Cancer Symposium that showed the Myriad's HRD (homologous recombination deficiency) test was significantly associated with cisplatin response in patients with triple negative breast cancer.
In this research study, Myriad's HRD test provided optimal prediction of platinum response in patients with triple negative disease (p=0.0003). The HRD score predicted all of the patients that experienced a complete response after pre-surgical treatment with platinum with a sensitivity of 100 percent. Furthermore, these results showed that the HRD score not only predicted drug response in triple negative patients but the HRD score also was generalizable across all breast cancer subtypes.
"Often tumors with high rates of double-strand DNA repair deficiency are especially difficult to treat," said Jerry Lanchbury, Ph.D., Chief Scientific Officer of Myriad Genetics. "It is difficult to know or assess the status of all DNA repair mechanisms, so the HRD test measures the effect by assessing the amount of DNA damage. Our data demonstrate that Myriad's HRD test has the capacity to precisely target DNA damaging therapy to the patients who are most likely to respond. The HRD test has the potential to support the targeted use of PARPs and other drugs in tumors that exhibit DNA repair scars."
This is the second research study to show that Myriad's HRD test predicts drug response to platinum therapy in triple-negative breast cancer patients. In a prior study, 70 percent of patients with an HRD score =10 responded to the carboplatin-based treatment, compared to only 20 percent of patients with an HRD score < 10 (p=0.0001). Using the HRD test instead of BRCA status identified more than three times as many patients as likely responders.
Myriad has announced two commercial collaborations to further develop the HRD test. In March, the Company announced it is conducting HRD testing on patients enrolled in PharmaMar's Phase 2 study of PM1183. In Nov. 2013, Myriad announced a collaboration with BioMarin that will use the HRD test to identify tumor types that may be sensitive to BioMarin's investigational product candidate, BMN-673. The Company also has two other undisclosed collaborations to evaluate HRD as a companion diagnostic.
About Myriad's HRD Test
Myriad's proprietary HRD test detects when a tumor has lost the ability to repair double-stranded DNA breaks resulting in increased susceptibility to DNA-damaging drugs. Myriad's HRD test includes three DNA-based measures of homologous recombination deficiency including: whole genome tumor loss of heterozygosity profiles (HRD-LOH), telomeric allelic imbalance (HRD-TAI) and large-scale state transitions (HRD-LST). All three scores are highly correlated with defects in BRCA1/2 and are associated with sensitivity to platinum agents. High HRD scores are prevalent in all breast cancer subtypes and most other major cancers. It is estimated that 490,000 people in the United States who are diagnosed with cancers annually are candidates for HRD testing with the view to recommend treatment with DNA-damaging agents such as platinum and PARP inhibitors.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website at: www.myriad.com and our social media channels: Twitter and Facebook.
Myriad, the Myriad logo, myRisk are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F. MYGN-G.
TheFinalCD
11 years ago
Myriad myRisk Hereditary Cancer(TM) Test Significantly Improves Detection of Women at Risk for Hereditary Cancer by 51 Percen...
Print
Alert
Myriad Genetics (NASDAQ:MYGN)
Intraday Stock Chart
Today : Thursday 12 December 2013
Click Here for more Myriad Genetics Charts.
Myriad Genetics, Inc. (Nasdaq:MYGN) today presented clinical data at the 2013 San Antonio Breast Cancer Symposium that showed the myRisk Hereditary Cancer test found 51 percent more patients with a higher risk of hereditary breast and ovarian cancer than did testing for the BRCA1 and BRCA2 genes alone. myRisk is a new diagnostic test that uses next-generation sequencing technology to evaluate 25 genes associated with eight major hereditary cancers including: breast, colorectal, ovarian, endometrial, pancreatic, prostate, gastric and melanoma.
This large prospective clinical validation study measured mutations in 25 cancer-causing genes among patients who were referred for BRCA1/2 testing. Among the 1,951 patients evaluated, 275 patients tested positive for a deleterious mutation with the myRisk test. Testing only for the BRCA1 and BRCA2 genes found only 182 of the mutation carriers, representing a 51 percent increase in hereditary breast and ovarian cancer mutation detection for the myRisk test. In this study, the accuracy of the myRisk test was 99.99 percent.
myRisk Hereditary Cancer has now been validated in approximately 5,000 patients in clinical studies. Today's results build on recently presented data that showed the myRisk test improved the detection of mutations in patients referred for hereditary colon cancer testing by 61 percent and with a 99.99 percent accuracy, which is equal to the gold standard Sanger DNA sequencing.
"Hereditary cancers are caused by mutations in many different genes and new genes linked to cancer have been recently identified. Testing only for one hereditary cancer syndrome may lead to missed mutations," said Richard J. Wenstrup, M.D., chief medical officer of Myriad. "The myRisk test evaluates 25 clinically actionable genes and significantly improves our ability to identify people at higher risk for hereditary cancer, which may lead to prevention or early detection with the ability to reduce cancer incidence and mortality."
The myRisk Hereditary Cancer test includes only clinically actionable genes. The majority of genes in the panel are reflected in the National Comprehensive Cancer Network (NCCN) guidelines and the clinical relevance of all 25 genes is well characterized in the peer-reviewed medical literature. Additionally, all genes in the myRisk panel have a high to moderately-high penetrance or lifetime risk of cancer for patients. For more information about hereditary cancer testing or myRisk, visit: www.myriad.com or take the hereditary cancer quiz at: www.hereditarycancerquiz.com.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website at: www.myriad.com and our social media channels: Twitter and Facebook.
Myriad, the Myriad logo and myRisk are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F. MYGN-G.
News
Market Data
Register to chat with like-minded investors on our interactive forums.
Ask ADVFN Intelligence (AI)
Monksdream
2 months ago
ClayTrader
5 years ago
cjstocksup
5 years ago
~MulaGreen~
6 years ago
getsmarter82
7 years ago
ValueInvestor15
8 years ago
$Pistol Pete$
9 years ago
Quokkie
10 years ago
